Voltron Therapeutics, a Lucius Partners Company, with the VIC at MGH Announces $5.88 Million Award from U.S. DoD
Award will advance the Self-Assembling Vaccine Platform for rapid [...]
Lucius Partners Portfolio Company Voltron Therapeutics, Inc Adds Manufacturing Expert to Scientific Advisory Board
Globally recognized manufacturing and product supply expert Tibor [...]
Lucius Partners Portfolio Company Voltron Therapeutics Announces Robust Immunogenicity Data: Key Prostate Cancer Target
Self Assembling Vaccine targets Prostate Stem Cell Antigen [...]
Voltron Therapeutics, a Lucius Partners Company, with the VIC at MGH Announces $5.88 Million Award from U.S. DoD
Voltron Therapeutics, a Lucius Partners Company, with the [...]
Lucius Partners Portfolio Company Voltron Therapeutics, Inc. Announces Sponsored Research Agreement with the Massachusetts General Hospital, Harvard Medical School, to Initiate a Pre-clinical Immuno-Oncology Trial
Lucius Partners Portfolio Company Voltron Therapeutics, Inc. Announces [...]
Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Poster Presentation at the Military Health System Research Symposium
Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, [...]
Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Definitive Proof of Concept Data for its Lead Oncology Candidate (VTX-067) in an HPV Related Tumor Challenge Study
Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, [...]
Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Industry Veteran Dr. Tony Hodges has Joined the Company as Senior Scientific Advisor
Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, [...]
Voltron Therapeutics, Inc., a Lucius Partners Company, Announces Initiation of Key Preclinical Study of VTX-067 in Immuno-Oncology
Voltron Therapeutics, Inc., a Lucius Partners Company, Announces [...]
Voltron Therapeutics, Inc., a Laidlaw Venture Partners Portfolio Company, Announces Industry Veteran Dr. Simon Pedder has Joined the Board of Directors
Voltron Therapeutics, Inc., a Laidlaw Venture Partners Portfolio [...]